Erythrocytosis after zidovudine for AIDS. 1991

C A Kennedy, and H S Griffith, and G E Mathisen

UI MeSH Term Description Entries
D008297 Male Males
D011086 Polycythemia An increase in the total red cell mass of the blood. (Dorland, 27th ed) Erythrocytosis,Erythrocytoses,Polycythemias
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000163 Acquired Immunodeficiency Syndrome An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. AIDS,Immunodeficiency Syndrome, Acquired,Immunologic Deficiency Syndrome, Acquired,Acquired Immune Deficiency Syndrome,Acquired Immuno-Deficiency Syndrome,Acquired Immuno Deficiency Syndrome,Acquired Immuno-Deficiency Syndromes,Acquired Immunodeficiency Syndromes,Immuno-Deficiency Syndrome, Acquired,Immuno-Deficiency Syndromes, Acquired,Immunodeficiency Syndromes, Acquired,Syndrome, Acquired Immuno-Deficiency,Syndrome, Acquired Immunodeficiency,Syndromes, Acquired Immuno-Deficiency,Syndromes, Acquired Immunodeficiency
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U

Related Publications

C A Kennedy, and H S Griffith, and G E Mathisen
May 1987, The New Zealand medical journal,
C A Kennedy, and H S Griffith, and G E Mathisen
January 1987, Nursing times,
C A Kennedy, and H S Griffith, and G E Mathisen
September 1990, Lancet (London, England),
C A Kennedy, and H S Griffith, and G E Mathisen
May 1989, Lancet (London, England),
C A Kennedy, and H S Griffith, and G E Mathisen
July 1990, Lancet (London, England),
C A Kennedy, and H S Griffith, and G E Mathisen
February 1989, Hospital practice (Office ed.),
C A Kennedy, and H S Griffith, and G E Mathisen
March 1992, Lancet (London, England),
C A Kennedy, and H S Griffith, and G E Mathisen
March 1992, Lancet (London, England),
C A Kennedy, and H S Griffith, and G E Mathisen
August 1989, JAMA,
C A Kennedy, and H S Griffith, and G E Mathisen
January 1990, The Journal of the American Board of Family Practice,
Copied contents to your clipboard!